bioMérieux is at the forefront of diagnostic technology, focusing on enhancing patient care and ensuring safety in various sectors, including healthcare, food safety, and pharmaceuticals. The company offers a comprehensive range of diagnostic solutions that aid in the detection and management of infectious diseases, antimicrobial resistance (AMR), and sepsis. Their innovative tools, such as the VIDAS® and BIOFIRE® panels, provide rapid and accurate results, enabling healthcare professionals to make informed decisions regarding antibiotic therapy. This commitment to actionable diagnostics is complemented by advanced analytics and collaborative services that optimize laboratory efficiency and improve patient outcomes.

In addition to their diagnostic capabilities, bioMérieux emphasizes the importance of antimicrobial stewardship, which aims to preserve the efficacy of antibiotics for future generations. Their integrated solutions support healthcare systems in implementing effective stewardship programs by providing insights into the appropriate use of antimicrobials. The company has established Antimicrobial Stewardship Centers of Excellence globally, partnering with leading hospitals to showcase best practices and generate valuable data on the impact of diagnostics in combating AMR. Through these initiatives, bioMérieux not only enhances clinical decision-making but also contributes to the sustainability of healthcare systems by reducing unnecessary treatments and associated costs.

France

bioMérieux develops in vitro products to diagnose infectious diseases, cancer and cardiovascular disease and to detect microorganisms in agri-foods, pharmaceuticals and cosmetics.BioFire COVID-19 test

bioMerieux

Company Details